Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Veracyte (VCYT) Enterprise Value: 2012-2025

Historic Enterprise Value for Veracyte (VCYT) over the last 13 years, with Sep 2025 value amounting to $2.4 billion.

  • Veracyte's Enterprise Value rose 1.91% to $2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 3.66%. This contributed to the annual value of $2.8 billion for FY2024, which is 57.84% up from last year.
  • As of Q3 2025, Veracyte's Enterprise Value stood at $2.4 billion, which was up 25.71% from $1.9 billion recorded in Q2 2025.
  • Veracyte's Enterprise Value's 5-year high stood at $3.3 billion during Q1 2021, with a 5-year trough of $1.0 billion in Q3 2022.
  • Over the past 3 years, Veracyte's median Enterprise Value value was $1.8 billion (recorded in 2023), while the average stood at $1.9 billion.
  • As far as peak fluctuations go, Veracyte's Enterprise Value spiked by 210.34% in 2021, and later crashed by 65.72% in 2022.
  • Over the past 5 years, Veracyte's Enterprise Value (Quarterly) stood at $2.8 billion in 2021, then plummeted by 43.77% to $1.5 billion in 2022, then rose by 15.78% to $1.8 billion in 2023, then surged by 57.84% to $2.8 billion in 2024, then rose by 1.91% to $2.4 billion in 2025.
  • Its Enterprise Value stands at $2.4 billion for Q3 2025, versus $1.9 billion for Q2 2025 and $2.1 billion for Q1 2025.